A single dose of erythropoietin in ST-elevation myocardial infarction

European Heart Journal

Volumn 31, Issue 21, 2010, Pages 2593-2600

  Voors, Adriaan A ^a   Belonje, Anne M S ^a   Zijlstra, Felix ^a   Hillege, Hans L ^a   Anker, Stefan D ^b   Slart, Riemer H J A ^a   Tio, René A ^a   Van 'T Hof, Arnoud ^c   Jukema, J Wouter ^d   Peels, Hans Otto J ^e   Henriques, José P S ^f   Ten Berg, Jurriën M ^g   Vos, Jeroen ^h   Van Gilst, Wiek H ^a   Van Veldhuisen, Dirk J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ISALA HOSPITAL   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Location Alkmaar   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g ST ANTONIUS HOSPITAL   (Netherlands)

^h AMPHIA HOSPITAL   (Netherlands)

Author keywords

Cardiovascular events; Erythropoietin; Infarct size; Left ventricular function; ST elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTENSION; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STROKE; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; COMBINED MODALITY THERAPY; ELECTROCARDIOGRAPHY; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RADIONUCLIDE VENTRICULOGRAPHY; RECOMBINANT PROTEINS; TREATMENT FAILURE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77958518157     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq304     Document Type: Article

References (26)

1. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006;48:2161-2167.
2. Tada H, Kagaya Y, Takeda M, Ohta J, Asaumi Y, Satoh K, Ito K, Karibe A, Shirato K, Minegishi N, Shimokawa H. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfu-sion. Cardiovasc Res 2006;71:466-477.
3. van der Meer P, Lipsic E, Henning RH, de Boer RA, Suurmeijer AJ, van Veldhuisen DJ, van Gilst WH. Erythropoetin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail 2004;6:853-859.
4. Lipsic E,van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Timing oferythropoietin treatment for cardioprotec-tion in ischemia/reperfusion. J Cardiovasc Pharmacol 2004;44:473-479.
5. van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin induces neo-vascularization and improves cardiac function in rats with heart failure after myo-cardial infarction. J Am Coll Cardiol 2005;46:125-133.
6. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. PNAS 2003; 100:4802-4806.
7. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ. A novel protective effect of ery-thropoietin in the infarcted heart. J Clin Invest 2003;112:999-1007.
8. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI. Erythropoie-tin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003;100:11612-11617.
9. Hirata A, Minamino T, Asanuma H, Fujita M, Wakeno M, Myoishi M, Tsukamoto O, Okada K, Koyama H, Komamura K, Takashima S, Shinozaki Y, Mori H, Shiraga M, Kitakaze M, Hori M. Erythropoietin enhances neovasculariza-tion of ischemic myocardium and improves left ventricular dysfunction after myo-cardial infarction in dogs. J Am Coll Cardiol 2006;48:176-184.
10. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, Koster J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovasculariza-tion. Eur Heart J 2007;28:2018-2027.
11. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, van Zonneveld AJ, Schoemaker RG, van Gilst WH, Zijlstra F, van Veldhuisen DJ. A single bolus of a long-acting erythropoietin analogue darbepoe-tin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006;20:135-141.
12. Ferrario M, Arbustini E, Massa M, Rosti V, Marziliano N, Raineri C, Campanelli R, Bertoletti A, De Ferrari GM, Klersy C, Angoli L, Bramucci E, Marinoni B, Ferlini M, Moretti E, Raisaro A, Repetto A, Schwartz PJ, Tavazzi L. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol 2009, doi:10.1016/j.ijcard. 2009.10.028.
13. Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J, Sobel BE. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol 2009;104:1035-1040.
14. Cleland JG, Coletta AP, Clark AL, Cullington D. Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA. Eur J Heart Fail 2009;11:622-630.
15. Belonje AM, Voors AA, van Gilst WH, Anker SD, Slart RH, Tio RA, Zijlstra F, van Veldhuisen DJ; HEBE III Investigators. Effects of erythropoietin after an acute myo-cardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J 2008;155:817-822.
16. Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Thrombus aspiration during primary percutaneous coronary intervention.N Engl J Med. 2008;358:557-567.
17. van der Vleuten PA, Slart RH, Tio RA, van der Horst IC, van Veldhuisen DJ, Dierckx RA, Zijlstra F. The feasibility of repeated left ventricular ejection fraction analysis with sequential single-dose radionuclide ventriculography. Nucl Med Commun 2005;26:711-715.
18. European Society of Cardiology; Heart Failure Association of the ESC (HFA); European Society of Intensive Care Medicine (ESICM), Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Tendera M, Auricchio A, Bax J, Böhm M, Corrà U, della Bella P, Elliott PM, Follath F, Gheorghiade M, Hasin Y, Hernborg A, Jaarsma T, Komajda M, Kornowski R, Piepoli M, Prendergast B, Tavazzi L, Vachiery JL, Verheugt FW, Zamorano JL, Zannad F. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
19. with non-STE acute coronary syndromes: results from a pilot study. Int J Cardiol 2009;131:285-287.
20. Belonje AM, Voors AA, van der Meer P, van Gilst WH, Jaarsma T, van Veldhuisen DJ. Endogenous erythropoietin and outcome in heart failure. Circulation 2010;121:245-251.
21. van der Meer P, Lok DJ, Januzzi JL, de la Porte PW, Lipsic E, van Wijngaarden J, Voors AA, van Gilst WH, van Veldhuisen DJ. Adequacy of endogenous erythro-poietin levels and mortality in anaemic heart failure patients. Eur Heart J 2008;29: 1510-1515.
22. Lipsic E, Westenbrink BD, van der Meer P, van der Harst P, Voors AA, van Veldhuisen DJ, Schoemaker RG, van Gilst WH. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haema-tocrit. Eur J Heart Fail 2008;10:22-29.
23. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents\-time for a reevaluation. N Engl J Med 2010;362:189-192.
24. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
25. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jähnig P, Herrmann M, Knauth M, Bähr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, Dengler R, Kastrup A, Bartels C; EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40: e647-e656.
26. Tang YD, Hasan F, Giordano FJ, Pfau S, Rinder HM, Katz SD. Effects of recombi-nant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial. Am Heart J 2009;158:941-947.